Conmed Corp.

NYSE:CNMD  
97.00
+0.47 (+0.49%)
Debt Financing / Related, Other Pre-Announcement

Conmed Agrees To Acquire Biorez For Cash Consideration Of $85 Mln

Published: 08/01/2022 20:32 GMT
Conmed Corp. (CNMD) - Conmed Announces Definitive Agreement to Acquire Biorez, Inc.proposed Deal for Cash Consideration of $85 Million at Closing.
Proposed Deal Includes Up to Additional $165 Million in Growth-based Earnout Payments Over a Four-year Period.
Proposed Deal Expected to Be Financed Through Existing Credit Facility.
Expects Deal to Add About $1 Million in Revenue to FY 2022 Revenue Guidance.
Expects Deal to Be About $0.10 to $0.15 Dilutive to Adjusted Cash Earnings per Share in 2022 and 2023.
Expects Deal to Be Accretive After 2022 and 2023.
Now Expects Full-year 2022 Adjusted Earnings per Share of $3.25 to $3.45.
FY2022 Earnings per Share View $3.42, Revenue View $1.12 Billion -- Refinitiv Ibes Data (analyst estimates).